You Mei, Li Xin, Zhao Huandong, Bai Zhongping, Liu Yushuang, Zhou Qing, Li Qiang, Yang Ruomei, Zhang Hexuan, He Hongbo, Zhu Zhiming, Yan Zhencheng
Department of Hypertension and Endocrinology, Center for Hypertension and Metabolic Diseases, Daping Hospital, Army Medical University, Chongqing Institute of Hypertension, Chongqing, China.
Chongqing Institute of Brain and Science, Chongqing, China.
Hypertens Res. 2025 Sep 19. doi: 10.1038/s41440-025-02375-w.
Primary aldosteronism (PA) is the most common form of secondary hypertension. However, its diagnosis is complicated by the need to withdraw interfering antihypertensive medications. Traditionally, 24-h urinary aldosterone (Uald) level measurement is employed as part of the oral sodium loading test to diagnose PA. However, the diagnostic efficacy of 24-h Uald for PA under a usual diet and without drug washout remains unclear. This retrospective study enrolled 583 patients with essential hypertension (EH) and 259 patients with PA, as well as an external validation cohort comprising 157 hypertensive patients. Patients with unilateral PA presented higher 24-h Uald levels than those with bilateral PA. Combination antihypertensive therapy reduced 24-h Uald levels in both EH and PA groups. Receiver operating characteristic curve analysis revealed similar areas under the curve for 24-h Uald diagnosing PA between the off-medication group (0.879, 95% CI = 0.834-0.925) and the on-medication group (0.851, 95% CI = 0.817-0.886). The optimal 24-h Uald cut-offs for PA diagnosis were 9.57 μg (sensitivity 79.4%, specificity 88.6%) in the off-medication group and 8.41 μg (sensitivity 75.8%, specificity 79.4%) in the on-medication group, with closely matched thresholds observed between patients receiving renin-increasing medications (8.52 μg) and those on combined renin-increasing and renin-suppressing therapy (8.39 μg). The diagnostic accuracy of 24-h Uald reached 89.2% in the external validation cohort. Our research indicates that the 24-h Uald test is clinically feasible for diagnosing PA without additional sodium supplementation or drug washout. However, the diagnostic threshold for 24-h Uald should be adjusted downward in patients on medications.
原发性醛固酮增多症(PA)是继发性高血压最常见的形式。然而,由于需要停用干扰性抗高血压药物,其诊断变得复杂。传统上,24小时尿醛固酮(Uald)水平测量被用作口服钠负荷试验的一部分来诊断PA。然而,在常规饮食且未进行药物洗脱的情况下,24小时Uald对PA的诊断效能仍不明确。这项回顾性研究纳入了583例原发性高血压(EH)患者和259例PA患者,以及一个由157例高血压患者组成的外部验证队列。单侧PA患者的24小时Uald水平高于双侧PA患者。联合抗高血压治疗降低了EH组和PA组的24小时Uald水平。受试者工作特征曲线分析显示,停药组(0.879,95%CI = 0.834 - 0.925)和服药组(0.851,95%CI = 0.817 - 0.886)中,24小时Uald诊断PA的曲线下面积相似。PA诊断的最佳24小时Uald截断值在停药组为9.57μg(敏感性79.4%,特异性88.6%),在服药组为8.41μg(敏感性75.8%,特异性79.4%),接受增加肾素药物治疗的患者(8.52μg)和接受增加肾素与抑制肾素联合治疗的患者(8.39μg)之间观察到阈值密切匹配。在外部验证队列中,24小时Uald的诊断准确性达到89.2%。我们的研究表明,24小时Uald试验在不额外补充钠或进行药物洗脱的情况下对诊断PA在临床上是可行的。然而,对于正在服药的患者,24小时Uald的诊断阈值应向下调整。